Navidea Biopharmaceuticals, Inc. (NAVB)
USD 0.0
(100.0%)
USD 0.0
(100.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2022 | -14.05 Million USD | -16.5% |
| 2021 | -12.06 Million USD | -12.6% |
| 2020 | -10.71 Million USD | 2.29% |
| 2019 | -10.96 Million USD | -1.06% |
| 2018 | -10.84 Million USD | 21.83% |
| 2017 | -13.87 Million USD | -524.11% |
| 2016 | -2.22 Million USD | 88.01% |
| 2015 | -18.55 Million USD | 32.87% |
| 2014 | -27.63 Million USD | 28.11% |
| 2013 | -38.43 Million USD | -37.33% |
| 2012 | -27.98 Million USD | -16.12% |
| 2011 | -24.1 Million USD | -281.94% |
| 2010 | -6.31 Million USD | -245.83% |
| 2009 | -1.82 Million USD | 40.01% |
| 2008 | -3.04 Million USD | -72.58% |
| 2007 | -1.76 Million USD | 49.06% |
| 2006 | -3.46 Million USD | 5.04% |
| 2005 | -3.64 Million USD | -82.29% |
| 2004 | -1.99 Million USD | -24.08% |
| 2003 | -1.61 Million USD | 46.17% |
| 2002 | -2.99 Million USD | -749.77% |
| 2001 | -352.2 Thousand USD | -127.37% |
| 2000 | 1.28 Million USD | 128.09% |
| 1999 | -4.58 Million USD | 83.91% |
| 1998 | -28.46 Million USD | -4.41% |
| 1997 | -27.26 Million USD | -16.81% |
| 1996 | -23.34 Million USD | -104.75% |
| 1995 | -11.4 Million USD | 3.39% |
| 1994 | -11.8 Million USD | -43.9% |
| 1993 | -8.2 Million USD | -173.33% |
| 1992 | -3 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 Q2 | -2.42 Million USD | -0.22% |
| 2023 Q1 | -2.42 Million USD | 24.26% |
| 2023 Q3 | -2.13 Million USD | 12.21% |
| 2022 Q3 | -4.95 Million USD | -69.4% |
| 2022 Q4 | -3.19 Million USD | 35.4% |
| 2022 FY | -14.05 Million USD | -16.5% |
| 2022 Q1 | -2.97 Million USD | 18.13% |
| 2022 Q2 | -2.92 Million USD | 1.9% |
| 2021 Q3 | -2.42 Million USD | 9.28% |
| 2021 Q4 | -3.63 Million USD | -50.27% |
| 2021 Q2 | -2.66 Million USD | 19.83% |
| 2021 FY | -12.06 Million USD | -12.6% |
| 2021 Q1 | -3.32 Million USD | -18.9% |
| 2020 Q4 | -2.8 Million USD | 3.38% |
| 2020 FY | -10.71 Million USD | 2.29% |
| 2020 Q1 | -2.67 Million USD | 3.63% |
| 2020 Q2 | -2.34 Million USD | 12.38% |
| 2020 Q3 | -2.89 Million USD | -23.84% |
| 2019 Q1 | -2.43 Million USD | -10.54% |
| 2019 FY | -10.96 Million USD | -1.06% |
| 2019 Q4 | -2.77 Million USD | 10.13% |
| 2019 Q3 | -3.08 Million USD | -15.42% |
| 2019 Q2 | -2.67 Million USD | -9.81% |
| 2018 FY | -10.84 Million USD | 21.83% |
| 2018 Q4 | -2.2 Million USD | 40.83% |
| 2018 Q3 | -3.72 Million USD | -53.42% |
| 2018 Q2 | -2.42 Million USD | 2.95% |
| 2018 Q1 | -2.49 Million USD | 29.0% |
| 2017 Q3 | -2.38 Million USD | 50.55% |
| 2017 Q4 | -3.51 Million USD | -47.55% |
| 2017 Q2 | -4.82 Million USD | -53.25% |
| 2017 FY | -13.87 Million USD | -524.11% |
| 2017 Q1 | -3.14 Million USD | -29.35% |
| 2016 Q2 | -579.98 Thousand USD | 77.42% |
| 2016 FY | -2.22 Million USD | 88.01% |
| 2016 Q4 | -2.43 Million USD | -172.46% |
| 2016 Q3 | 3.35 Million USD | 679.06% |
| 2016 Q1 | -2.56 Million USD | 1.24% |
| 2015 FY | -18.55 Million USD | 32.87% |
| 2015 Q4 | -2.6 Million USD | 39.84% |
| 2015 Q2 | -3.81 Million USD | 51.25% |
| 2015 Q3 | -4.32 Million USD | -13.45% |
| 2015 Q1 | -7.81 Million USD | -74.63% |
| 2014 Q3 | -5.36 Million USD | 41.81% |
| 2014 Q2 | -9.21 Million USD | -7.42% |
| 2014 FY | -27.63 Million USD | 28.11% |
| 2014 Q1 | -8.57 Million USD | 34.28% |
| 2014 Q4 | -4.47 Million USD | 16.53% |
| 2013 FY | -38.43 Million USD | -37.33% |
| 2013 Q4 | -13.05 Million USD | -31.52% |
| 2013 Q2 | -8.45 Million USD | -20.73% |
| 2013 Q3 | -9.92 Million USD | -17.36% |
| 2013 Q1 | -7 Million USD | 0.32% |
| 2012 FY | -27.98 Million USD | -16.12% |
| 2012 Q4 | -7.02 Million USD | 22.52% |
| 2012 Q3 | -9.06 Million USD | -68.36% |
| 2012 Q2 | -5.38 Million USD | 17.21% |
| 2012 Q1 | -6.5 Million USD | 28.05% |
| 2011 Q2 | -2.17 Million USD | 37.3% |
| 2011 FY | -24.1 Million USD | -281.94% |
| 2011 Q4 | -9.04 Million USD | -39.7% |
| 2011 Q3 | -6.47 Million USD | -196.94% |
| 2011 Q1 | -3.47 Million USD | -148.65% |
| 2010 Q2 | -928.72 Thousand USD | 46.5% |
| 2010 Q3 | -2.24 Million USD | -142.09% |
| 2010 Q4 | -1.39 Million USD | 37.81% |
| 2010 FY | -6.31 Million USD | -245.83% |
| 2010 Q1 | -1.73 Million USD | -313.12% |
| 2009 FY | -1.82 Million USD | 40.01% |
| 2009 Q4 | -420.19 Thousand USD | -29.7% |
| 2009 Q2 | -927.63 Thousand USD | -251.9% |
| 2009 Q3 | -323.97 Thousand USD | 65.07% |
| 2009 Q1 | -263.6 Thousand USD | 65.1% |
| 2008 Q3 | -1.51 Million USD | -233.79% |
| 2008 Q2 | -454.24 Thousand USD | -43.6% |
| 2008 Q1 | -316.32 Thousand USD | -16.24% |
| 2008 Q4 | -755.31 Thousand USD | 50.18% |
| 2008 FY | -3.04 Million USD | -72.58% |
| 2007 FY | -1.76 Million USD | 49.06% |
| 2007 Q4 | -272.13 Thousand USD | -202.21% |
| 2007 Q3 | -90.04 Thousand USD | 87.28% |
| 2007 Q2 | -708.01 Thousand USD | -2.23% |
| 2007 Q1 | -692.58 Thousand USD | 24.95% |
| 2006 Q1 | -635.96 Thousand USD | 36.74% |
| 2006 FY | -3.46 Million USD | 5.04% |
| 2006 Q3 | -1.33 Million USD | -137.69% |
| 2006 Q2 | -563.15 Thousand USD | 11.45% |
| 2006 Q4 | -922.81 Thousand USD | 31.06% |
| 2005 FY | -3.64 Million USD | -82.29% |
| 2005 Q2 | -1.07 Million USD | -87.51% |
| 2005 Q4 | -1 Million USD | -1.1% |
| 2005 Q3 | -994.33 Thousand USD | 7.29% |
| 2005 Q1 | -571.99 Thousand USD | 34.81% |
| 2004 Q1 | -511.01 Thousand USD | 1.19% |
| 2004 Q2 | -408.59 Thousand USD | 20.04% |
| 2004 Q3 | -202 Thousand USD | 50.56% |
| 2004 Q4 | -877.48 Thousand USD | -334.39% |
| 2004 FY | -1.99 Million USD | -24.08% |
| 2003 Q1 | -472.87 Thousand USD | -182.39% |
| 2003 FY | -1.61 Million USD | 46.17% |
| 2003 Q4 | -517.19 Thousand USD | 10.17% |
| 2003 Q3 | -575.71 Thousand USD | -1169.98% |
| 2003 Q2 | -45.33 Thousand USD | 90.41% |
| 2002 Q2 | -883.82 Thousand USD | -4.25% |
| 2002 Q1 | -847.76 Thousand USD | -28.79% |
| 2002 FY | -2.99 Million USD | -749.77% |
| 2002 Q4 | -167.45 Thousand USD | 84.69% |
| 2002 Q3 | -1.09 Million USD | -23.77% |
| 2001 Q3 | 133.38 Thousand USD | -9.05% |
| 2001 FY | -352.2 Thousand USD | -127.37% |
| 2001 Q2 | 146.65 Thousand USD | 448.45% |
| 2001 Q1 | 26.74 Thousand USD | -92.19% |
| 2001 Q4 | -658.25 Thousand USD | -593.5% |
| 2000 Q4 | 342.51 Thousand USD | -21.13% |
| 2000 Q2 | 565.29 Thousand USD | 1126.47% |
| 2000 Q1 | -55.07 Thousand USD | 85.88% |
| 2000 FY | 1.28 Million USD | 128.09% |
| 2000 Q3 | 434.25 Thousand USD | -23.18% |
| 1999 Q3 | -1.85 Million USD | -68.18% |
| 1999 Q2 | -1.1 Million USD | 21.43% |
| 1999 Q4 | -390 Thousand USD | 78.92% |
| 1999 Q1 | -1.4 Million USD | 88.3% |
| 1999 FY | -4.58 Million USD | 83.91% |
| 1998 Q4 | -11.96 Million USD | -214.96% |
| 1998 Q1 | -7.2 Million USD | 14.94% |
| 1998 FY | -28.46 Million USD | -4.41% |
| 1998 Q2 | -5.3 Million USD | 26.39% |
| 1998 Q3 | -3.8 Million USD | 28.3% |
| 1997 Q2 | -7.7 Million USD | -42.59% |
| 1997 Q4 | -8.46 Million USD | -51.15% |
| 1997 Q3 | -5.6 Million USD | 27.27% |
| 1997 FY | -27.26 Million USD | -16.81% |
| 1997 Q1 | -5.4 Million USD | 29.34% |
| 1996 FY | -23.34 Million USD | -104.75% |
| 1996 Q4 | -7.64 Million USD | -10.75% |
| 1996 Q3 | -6.9 Million USD | -27.78% |
| 1996 Q2 | -5.4 Million USD | -35.0% |
| 1996 Q1 | -4 Million USD | -21.21% |
| 1995 Q3 | -2.9 Million USD | -7.41% |
| 1995 Q4 | -3.3 Million USD | -13.79% |
| 1995 FY | -11.4 Million USD | 3.39% |
| 1995 Q2 | -2.7 Million USD | 6.9% |
| 1995 Q1 | -2.9 Million USD | 27.5% |
| 1994 FY | -11.8 Million USD | -43.9% |
| 1994 Q1 | -2.6 Million USD | -4.0% |
| 1994 Q2 | -2.1 Million USD | 19.23% |
| 1994 Q3 | -2.9 Million USD | -38.1% |
| 1994 Q4 | -4 Million USD | -37.93% |
| 1993 Q4 | -2.5 Million USD | -13.64% |
| 1993 Q2 | -2 Million USD | -53.85% |
| 1993 Q3 | -2.2 Million USD | -10.0% |
| 1993 FY | -8.2 Million USD | -173.33% |
| 1993 Q1 | -1.3 Million USD | -8.33% |
| 1992 FY | -3 Million USD | 0.0% |
| 1992 Q3 | -800 Thousand USD | 0.0% |
| 1992 Q4 | -1.2 Million USD | -50.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -31.91 Million USD | 55.975% |
| Ampio Pharmaceuticals, Inc. | -9.51 Million USD | -47.624% |
| Armata Pharmaceuticals, Inc. | -40.89 Million USD | 65.637% |
| Actinium Pharmaceuticals, Inc. | -51.92 Million USD | 72.937% |
| Azitra, Inc. | -7.61 Million USD | -84.482% |
| Can-Fite BioPharma Ltd. | -8.19 Million USD | -71.457% |
| Chromocell Therapeutics Corporation | -6.86 Million USD | -104.755% |
| Calidi Biotherapeutics, Inc. | -28.99 Million USD | 51.535% |
| CEL-SCI Corporation | -31.47 Million USD | 55.36% |
| iBio, Inc. | -16.63 Million USD | 15.529% |
| Lineage Cell Therapeutics, Inc. | -24.73 Million USD | 43.19% |
| MAIA Biotechnology, Inc. | -20.18 Million USD | 30.38% |
| Matinas BioPharma Holdings, Inc. | -23.76 Million USD | 40.878% |
| NovaBay Pharmaceuticals, Inc. | -5 Million USD | -180.849% |
| NanoViricides, Inc. | -8.51 Million USD | -64.992% |
| Oragenics, Inc. | -20.9 Million USD | 32.787% |
| BiomX Inc. | -27.68 Million USD | 49.247% |
| BiomX Inc. | -27.68 Million USD | 49.247% |
| Protalix BioTherapeutics, Inc. | 10.46 Million USD | 234.33% |
| Palatin Technologies, Inc. | -22.49 Million USD | 37.541% |
| Scorpius Holdings, Inc. | -42.03 Million USD | 66.571% |
| Theriva Biologics, Inc. | -21.43 Million USD | 34.437% |